Skip to main content
. 2015 Nov 3;6(39):42183–42196. doi: 10.18632/oncotarget.5619

Figure 4. Inhibition of the mTOR pathway blocks cell growth in HRAS mutant cell lines.

Figure 4

A. HRAS mutant and wild-type cells were left untreated or treated with indicated concentrations of Everolimus for 96 hours. Next, cell growth was measured by Cell Titer Glo according to the manufacturer's instructions (left panel). In addition, all HRAS mutant cell lines were treated with 10nM Everolimus for 1 hour. Then, cells were lysed and analysed by Western blot applying phospho-S6 antibody and anti-actin antibodies for loading control (right panel). B. KNS-62 and T24 cells were treated with 250nM AZD6244, 250nM MEK162, 5nM of Everolimus, 250nM AKT8055 or combinations thereof as indicated for 1 hour. Then, cells were lysed and analysed by Western blot. CIs are indicated. C. KNS-62 and T24 cells were left untreated or treated with indicated concentrations of Everolimus and AZD6244/MEK162 for 96 hours. Then, cell growth was measured by Cell Titer Glo according to the manufacturer's instructions. CIs are indicated. D. Same as in C., but the mTOR inhibitor AZD8055 was used instead of Everolimus. CIs are indicated.